A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Romosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 01 Sep 2017 Planned End Date changed from 26 May 2018 to 14 May 2018.
- 01 Sep 2017 Planned primary completion date changed from 25 Feb 2018 to 13 Feb 2018.
- 01 Sep 2017 Status changed from recruiting to active, no longer recruiting.